Top in endocrinology: Dapagliflozin, new integrated continuous glucose monitor

New data from the DAPA-HF trial showed that dapagliflozin was associated with a 32% lower risk for new-onset type 2 diabetes among patients with heart failure. It was the top story in endocrinology last week.

Another top story was about the recent FDA approval of a next-generation integrated continuous glucose monitoring system for patients with diabetes.

Read these and more top stories in endocrinology below:

DAPA-HF: Dapagliflozin reduces new-onset diabetes among adults with heart failure

Adults with heart failure assigned the SGLT2 inhibitor dapagliflozin (Farxiga, AstraZeneca) had a 32% lower risk for new-onset type 2 diabetes over 18 months of follow-up vs. placebo, according to a planned analysis of DAPA-HF trial data. Read more.

FDA clears next-generation integrated continuous glucose monitor

The FDA has cleared a next-generation integrated continuous glucose monitoring system for adults and children aged 4 years and older with diabetes, according to a press release from Abbott. Read more.

Aggressive management in stage 3 CKD preserves kidney function in diabetes

Adults with type 2 diabetes and a low estimated glomerular filtration rate must be more aggressively managed with tailored treatment options to preserve kidney function and reduce morbidity and mortality risk. Read more.

Undiagnosed liver disease common among US adults with type 2 diabetes

Among U.S. adults with type 2 diabetes attending primary care and endocrinology clinics, less than 40% of those found to have liver fibrosis had elevated aspartate aminotransferase and alanine aminotransferase, according to study data. Read more.

REDUCE-IT DIABETES: Icosapent ethyl lowers CV event risk in type 2 diabetes

Icosapent ethyl therapy (Vascepa, Amarin) provides robust cardiovascular benefits in statin-treated adults with type 2 diabetes, with large relative and absolute risk reductions in first and total CV events, study data show. Read more.